Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
4(66.7%)
Phase 3
2(33.3%)
6Total
Phase 1(4)
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT06790394Phase 1Recruiting

Test-retest Study With [18F]FBB in Cardiac Amyloidosis

Role: lead

NCT05184088Phase 3Recruiting

Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis

Role: lead

NCT05187546Phase 1Completed

Test-retest Study With [18F]PI-2620 in PSP-RS and NDC

Role: lead

NCT04715750Phase 1Completed

Evaluation of Imaging Characteristics of [18F]PI-2620 PET in AD and PSP Patients Using High and Low Specific Activity

Role: lead

NCT05490576Phase 1Active Not Recruiting

Tau And Connectomics In TES Study

Role: collaborator

NCT05143528Phase 3Not Yet Recruiting

Evaluating the Efficacy and Safety of Nilotinib BE in Subjects With Early Alzheimer's Disease

Role: collaborator

All 6 trials loaded